What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2022-08-15 compared with 2022-05-13 · 33 added, 24 removed, 268 unchanged (18% of the section changed)

Other Information

- See exhibit index below.

Amended and Restated Certificate of Incorporation of the Company, as amended, along with Certificates of Designations (incorporated by reference to exhibits of the Company’s Registration Statement on Form S-1 (No.

Exhibits - See exhibit index below.

and Restated Certificate of Incorporation of the Company, as amended, along with Certificates of Designations (incorporated by reference

to exhibits of the Company’s Registration Statement on Form S-1 (No.

33-93314) filed November 2, 1995).

1 unchanged sentence

001-13441) filed September 16, 2011).

Amendment to Certificate of Incorporation(incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A (No.

to Certificate of Incorporation (incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement on

Schedule 14A (No.

000-27072) filed June 27, 2016).

Amendment to Certificate of Incorporation(incorporated by reference to exhibit 3.11 to the Company’s Current report on Form 8-K (No.

to Certificate of Incorporation (incorporated by reference to exhibit 3.11 to the Company’s Current report on Form 8-K (No.

001-27072) filed June 5, 2019).

5 unchanged sentences

000-27072) filed June 10, 2016).

Specimen certificate representing our Common Stock (incorporated by reference to exhibits of the Company’s Registration Statement on Form S-1 (No.

certificate representing our Common Stock (incorporated by reference to exhibits of the Company’s Registration Statement on

Form S-1 (No.

33-93314) filed November 2, 1995).

43 unchanged sentences

001-27072) for the year ended December 31, 2021).

Form of Confidentiality, Invention and Non-Compete Agreement (incorporated by reference to exhibits of the Company’s Registration Statement on Form S-1 (No.

of Confidentiality, Invention and Non-Compete Agreement (incorporated by reference to exhibits of the Company’s Registration

Statement on Form S-1 (No.

33-93314) filed November 2, 1995).

Form of Clinical Research Agreement (incorporated by reference to exhibits of the Company’s Registration Statement on Form S-1 (No.

of Clinical Research Agreement (incorporated by reference to exhibits of the Company’s Registration Statement on Form S-1 (No.

33-93314) filed November 2, 1995.

186 unchanged sentences

001-27072) for the year ended December 31, 2021).

24, 2022 Consulting Agreement with Ellen Lintal (Portions of this agreement have been redacted in compliance with Regulation S-K

Item 601(b)(10)) (incorporated by reference to exhibit 10.79 to the Company’s Annual report on Form 10-K (No.

March 24, 2022 Consulting Agreement with Ellen Lintal (Portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to exhibit 10.79 to the Company’s Annual report on Form 10-K (No.

001-27072) for the year ended December 31, 2021).

11 unchanged sentences

001-27072) filed April 12, 2022).

January 16, 2021 Letter from MBAF (incorporated by reference to exhibit 10.1 to the Company’s Current report on Form 8-K (No.

001-27072) filed APRIL 27, 2020).

June 13, 2022 Project Work Order with Amarex Clinical Research LLC.

for a Randomized Double Blind, Placebo Controlled study to Evaluate the Efficacy and Safety of Ampligen in Patients with Post Covid Conditions (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to exhibit 10.1 to the Company’s Current Report on Form 8-K (No.

001-27072) filed June 17, 2022).

June 16, 2022 Lease agreement entered into with New Jersey Economic Development Authority for 5,210 square-foot R&D facility at the New Jersey Bioscience Center (incorporated by reference 10.1 to the Company’s Current Report on Form 8-K (No.001-27072) filed June 21, 2022).

June 27, 2022 First Amendment to Agreement of Sale and Purchase with Acellories, Inc.*

August 2, 2022 Second Amendment to Agreement of Sale and Purchase with Acellories, Inc.*

August 10, 2022 Termination agreement with Shenzhen Smoore Technology Limited *

List of Subsidiaries (incorporated by reference to exhibit 21 to the Company’s Annual report on Form 10-K (No.

001-27072) for the year ended December 31, 2021).

Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer.

Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer.

Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer.

Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer.

The following materials from AIM’ Annual Report on Form 10-K for

the year ended December 31, 2019, formatted in Inline eXtensible Business Reporting Language (“XBRL”):

(i) the Condensed

Consolidated Statements of Income;

(ii) the Condensed Consolidated Balance Sheets;

(iii) the Condensed Consolidated Statements of

Certification

pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer.

Certification

pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer.

Certification

pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer.

Certification

pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer.

following materials from AIM’ Annual Report on Form 10-K for the year ended December 31, 2019, formatted in eXtensible Business

Reporting Language (“XBRL”):

(i) the Condensed Consolidated Statements of Income;

(ii) the Condensed Consolidated Balance

(iii) the Condensed Consolidated Statements of Cash Flows;

and (iv) Notes to Condensed Consolidated Financial Statements.

Cover Page Interactive

Data File (embedded within the Inline XBRL document).

Filed herewith.

to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed

4 unchanged sentences

Financial Officer

August 15, 2022

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information